
ALLERGIC CONJUNCTIVITIS

Leonard Bielory, MD, Mitchell H. Friedlaender, MD,
and Hiroshi Fujishima, MD

Allergic conjunctivitis affects approximately 25% of the general population, and is a common clinical problem for ophthalmic and allergic practices.¹⁷ In one study of 5000 allergic children, 32% had ocular disease as the single manifestation of their allergies.³³ Although many cases are seasonal, a large number of patients have year-round symptoms. Ocular allergies have been touted to compose 10% of ophthalmologic practice, 25% of allergy/clinical immunologic practice, and 5% of the general pediatric and internal medicine practice; however, the various definitions and treatment regimens make them difficult to diagnose and frustrating to treat.

The conjunctiva can be affected by allergies to airborne pollens, animal dander, and other environmental antigens. The conjunctiva, like the nasal mucosa, is an active immunologic tissue that undergoes lymphoid hyperplasia in response to a stimulant.²⁶ The conjunctiva represents a thin mucous membrane that extends from the limbus of the eye to the lid margin of the eyelid. The conjunctiva is divided into three portions: the bulbar conjunctiva, which covers the anterior portion of the sclera; the palpebral conjunctiva, which lines the inner surface of the eyelids; and the space bounded by the bulbar and palpebral conjunctiva, which is the fornix or the conjunctival sac. The conjunctiva is histologically divided into two layers: epithelial and substantia propria layers. The epithelial layer is composed of 2 to 5 cells of stratified columnar cells whereas the lamina propria is composed of loose connective tissue.

As in other forms of allergic inflammation, the mast cell plays a key role. Mast cells are widely distributed, especially in connective tissue and

From the Division of Ophthalmology, Scripps Clinic and Research Foundation, La Jolla, California (MHF); the Division of Rheumatology and Immunology, Harvard Medical School, Boston, Massachusetts (HF); and the Division of Allergy and Immunology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, New Jersey (LB)

mucosal surfaces. In the eye they are classically found in the conjunctiva, choroid, ciliary body, iris, and optic nerve. Mast cells ($6000/\text{mm}^3$) and other inflammatory cells are normally found in the substantia propria, just below the epithelial junction. Initial reports of conjunctival mast cell populations were based on the differential physiological response to compound 48/80 which causes connective tissue mast cells to degranulate, but not mucosal mast cells. In the rat animal model the response to a single application of 48/80 suggested that the conjunctival mast cells primarily belong to the connective tissue type of mast cells.⁵ Mononuclear cell populations of the normal human conjunctiva are primarily located in the epithelium and include Langerhans' cells (CD1^+ ; 85 ± 16 cells/ mm^2) and CD3^+ lymphocytes (189 ± 27 cells/ mm^2) with a $\text{CD4}^+/\text{CD8}^+$ ratio of 0.75.⁴⁰ The Langerhans' cells are known to facilitate immune reactions in the skin by functioning as an antigen-presenting cell, but their function in the cornea has yet to be clarified.²² Interestingly, the Langerhans' cells of the eye are recognized by the CD1^+ marker, but not the CD6^+ thymocyte marker, which is commonly found on Langerhans' cells of the skin or in histiocytes from patients with histiocytosis X.³⁶ Normal ocular epithelium does not contain any mast cells, eosinophils, or basophils, although in ocular inflammatory disorders, such as vernal and giant papillary conjunctivitis, such cells are seen, as evidenced by the conjunctival deposition of eosinophil major basic protein deposition⁴³; however, conjunctival epithelial cells may also play an active role in allergic inflammation as they have been shown to express RANTES in large amounts when stimulated with tumor necrosis factor- α or interferon- γ in vitro.²⁰

Histamine concentration in tears can reach values greater than 100 ng/mL compared with normal values of 5 to 15 ng/mL.²⁵ Histamine can cause similar changes in the eye, as it does in other parts of the human body, which include capillary dilatation, increased vascular permeability, and smooth muscle contraction. Histamine concentration of 240 nmol/L ($10 \mu\text{L}$ of a 50 ng/mL histamine phosphate concentration) can cause conjunctival redness and increased vascular permeability in 50% of the subjects studied. Tear histamine levels found in nonatopic controls are not different than allergic patients during their symptom-free periods.²⁷

HISTORY

A detailed history may reveal recent exposure to individuals with conjunctivitis or upper respiratory tract infection either within the family, school, or workplace. Such a history may help confirm an adenovirus infection in an endemic area. Knowledge of the patient's sexual activities and any associated discharge may suggest chlamydial disease or *Neisseria* infection. Frequently, the patient will not mention the use of over-the-counter topical medications, such as vasoconstrictors or artificial tears, cosmetics, or contact lens wear. Direct questioning often reveals

the use of these products or other topical and systemic medications, all capable of producing inflammation that can mimic seasonal or perennial allergic conjunctivitis. A knowledge of any systemic disease, such as rheumatoid arthritis or other collagen vascular diseases, raises the clinician's suspicion for keratoconjunctivitis sicca, although a patient referred for irritated eyes with thyroid dysfunction would suggest superior limbic keratoconjunctivitis.

The offending allergens vary from one location to another, but the symptoms and signs appear to be similar throughout the world. Often symptoms are not severe enough to precipitate a visit to the allergist or the ophthalmologist. Among patients who seek help, some may not require treatment and others may simply be able to avoid the allergens responsible for their disease.

Symptoms usually consist of low-grade ocular and periocular itching, tearing, burning, stinging, photophobia, and watery discharge. Redness and itching seem to be the most consistent symptoms. Although symptoms persist throughout the allergy season, they are subject to exacerbations and remissions, depending on the weather and the patient's activities. Symptoms are generally worse when the weather is warm and dry; cooler temperatures and rain tend to alleviate symptoms. Although itching is generally mild, occasionally it can be severe, and rarely patients may be incapacitated by their symptoms. Many of the symptoms of ocular allergy are nonspecific, such as tearing, irritation, stinging, burning, and photophobia.

The symptom of itching is strikingly characteristic of allergic conjunctivitis. It is often said that ocular itching implies allergy until proven otherwise. Furthermore, ocular itching is rare in other conditions, although it is not unknown. Patients with blepharitis, dry eye, and other types of conjunctivitis may experience itching. It is worthwhile to pinpoint the location of itching. For example, patients who complain of ocular itching may be presumed to be describing conjunctival itching; however, some patients with ocular itching are describing symptoms related to the skin of their eyelids. Careful questioning can distinguish itching of the conjunctiva from itching of the eyelid skin. Although the former is usually associated with allergic rhinoconjunctivitis, which affects the conjunctiva, the latter may indicate contact allergy, which affects both the skin and the conjunctiva. The discharge is usually watery and may be described as tearing. Sometimes there is a scant mucus component. The discharge may range from serous (watery) to mucopurulent and grossly purulent. A stringy or ropy discharge is characteristic of allergy. In severe forms of allergic conjunctivitis, such as vernal conjunctivitis, tenacious strands of mucus can be removed from the eye by the patient or the doctor. Environmental allergens are ubiquitous and nonselective, most commonly affecting both eyes at once. Conjunctival injection is commonly associated with discomfort, and when the patient complains of ocular pain one must search for other causes.

In allergic patients it is unusual to have conjunctival symptoms without nasal symptoms. One expects the nasal mucosa to react in the

same fashion as the conjunctival mucosa; however, at times one will encounter allergic patients whose only symptoms appear to be ocular. These patients may indicate that they do not have systemic allergies because they have not experienced typical allergic rhinitis. It is not known why the conjunctiva should be the main target in certain patients with allergies. There may be emotional or psychological factors that make ocular symptoms more disturbing than nasal symptoms. Often, when patients deny nasal or respiratory symptoms, careful questioning can sometimes elicit such symptoms, even though they may be mild.

EXAMINATION

The eye should be carefully examined for evidence of eyelid involvement (i.e., blepharitis, dermatitis, swelling, discoloration, ptosis blepharospasm), conjunctival involvement (i.e., chemosis), hyperemia, palpebral and bulbar papillae, cicatrization, and presence of increased or abnormal-appearing secretions, as well as a fundoscopic examination for uveitis associated with autoimmune disorders and cataracts associated with atopic disorders and chronic steroid use.

The bulbar conjunctiva is examined by looking directly at the eye and asking the patient to look up and then down while gently retracting the opposite lid (i.e., looking down while holding up the upper eyelid). Examination of the palpebral (tarsal) conjunctiva is performed by asking the patient to look down, grasping the upper lid at its base with a cotton swab on the upper portion of the lid, and then pulling out and up. Have the patient looking down during the examination. To return the lid to its normal position, have the patient look up. The lower tarsal conjunctiva is examined by everting the lower eyelid while placing a finger near the lid margins and drawing downward. Conjunctivitis can be differentiated from inflammation involving the anterior portion of the eye by the involvement of the fornix and the palpebral conjunctiva. A velvety, beefy-red conjunctiva suggests a bacterial cause. A "milky" appearance, the result of obscuration of blood vessels by conjunctival edema (Fig. 1), is characteristic of allergy. The combination of these two features gives the conjunctiva a pinkish or milky appearance. Because the conjunctival blood vessels are partially obscured, they are best evaluated with a slit-lamp microscope. Occasionally, chemosis is so marked that it is obvious without magnification. If edema is severe, patients exhibit periorbital edema (Fig. 2). This is more prominent around the lower lids because of gravity. Ecchymosis, or the "allergic shiner," has also been described in allergic patients, and is thought to be the result of impaired venous return from the skin and subcutaneous tissues, although proof of this is lacking.⁴⁴

The signs of allergic conjunctivitis may not be terribly striking. One expects the allergic eye to show mild to moderate redness. Severe redness would suggest a different diagnosis. It does seem, however, that




Figure 1. Chemosis and injection of allergic conjunctivitis.

swelling or chemosis is somewhat out of proportion to the amount of redness that is present. No doubt some of the mediators released during allergic inflammation promote extravasation of serum out of the blood vessels and into the surrounding tissues. If chemosis is subtle, it can sometimes be detected at the medial aspect of the bulbar conjunctiva in the region of the plica semilunaris. This looser conjunctival tissue may appear more elevated and boggy than expected.

It is worthwhile to examine the superior limbus and the superior tarsal conjunctiva. In more severe allergies, these tissues are the site of Trantas' dots and giant papillae, respectively. They appear to be peculiar, anatomic targets for allergic inflammation, and sometimes they will provide a subtle indication of the activity of ocular allergic disease. The direct (hand-held) ophthalmoscope provides approximately $14\times$ magnification. The physician may need to adjust the ophthalmoscope



Figure 2. Periorbital edema in acute ocular allergy.

power setting to accommodate the patient's or his or her own refractive errors; minus (red numbered) lenses correct for near sightedness whereas the positive (green numbered) lenses correct for farsighted errors. While using the lens, settings of +8 with the ophthalmoscope held close to the patient's eye assist the physician in focusing on the anterior segment to reveal corneal opacities or changes in the iris or lens. Decreasing the power of the lens from +8 to -8 increases the depth of focus so that the examiner may move from the anterior segment progressively through the vitreous and reach the retina. The red-free (green) light filter is employed to sharply delineate small aneurysms and hemorrhages as black in color in patients with autoimmune disorders (e.g., systemic lupus erythematosus, vasculitis).

SEASONAL AND PERENNIAL ALLERGIC CONJUNCTIVITIS

Seasonal and perennial allergic conjunctivitis are the most prevalent forms of ocular allergy.³² Of the two, seasonal allergic conjunctivitis is more common. The importance of this condition is more due to its frequency than its severity.⁴⁴

Seasonal Allergic Conjunctivitis

Seasonal allergic conjunctivitis (SAC) is the most common form of allergic conjunctivitis, representing half of all cases of allergic conjunctivitis. The onset of symptoms is seasonally related to specific circulating aeroallergens. Grass pollens have been noted to be associated with increased ocular symptoms during the spring and in some areas during the fall ("Indian summer"). The ocular symptoms are frequently associated with nasal or pharyngeal complaints. The patients present with complaints of itchy eyes or a burning sensation with a watery discharge. A white exudate may form during the acute state, which becomes stringy in the chronic form. Rarely, SAC may also include corneal symptoms of photophobia and blurring of vision. The conjunctival surfaces are mildly injected with various levels of chemosis (conjunctival edema). Lid edema may sometimes occur as well as papillary hypertrophy along the tarsal conjunctival surface. Symptoms are usually bilateral, although the degree of involvement may not be symmetrical. Affected individuals usually have a history of atopy. Allergic conjunctivitis, unlike several other ocular diseases, is seldom followed by permanent visual impairment.

Conjunctival cytology has revealed eosinophil infiltration in 25% of patients with SAC. Elevated serum IgE levels have been noted in 78% of patients with SAC whereas tear fluid IgE is present in almost all (96%) tear fluid samples.

Perennial Allergic Conjunctivitis

Perennial allergic conjunctivitis (PAC) is considered to be a variant of SAC that persists throughout the year, although 79% of patients with PAC experience a seasonal exacerbation. Dust mites, animal dander, and feathers are the most common airborne allergens implicated in PAC, and the latter is more likely than SAC to be associated with perennial rhinitis. Patients with PAC and SAC are similar in age and sex, and both patient groups have the same prevalence of associated symptoms of asthma or eczema. The prevalence appears to be much lower than SAC (3:5:10,000).¹³ Symptoms are noted throughout the year, although seasonal exacerbations can be noted in 79%. PAC is similar to SAC in affected age range and length of history, although SAC was subjectively more severe. When patients with PAC are compared to patients with SAC, a history of exposure to house dust was more common (42% versus 0%), as well as the association of perennial rhinitis (75% versus 12%).

SAC and PAC are typical mast cell-mediated hypersensitivity reactions affecting the eye, in which the allergens react with specific IgE antibodies bound to the surface of conjunctival mast cells. The activation of mast cells leads to the release of powerful vasoactive amines, which is responsible for the itching, vasodilatation, and edema encountered in allergic conjunctivitis.

Patients with SAC and PAC have been noted to have aeroallergen sensitivity and elevated IgE in both tears and serum. Differences between PAC and SAC include the findings that 89% of patients with PAC had specific serum IgE for house dust compared with 43% of patients with SAC. Similarly, 78% of patients with PAC have tear-specific IgE for house dust whereas no patients with SAC had measurable IgE specific for house dust in tears. Mediators released by the degranulation of mast cells include preformed mediators, such as histamine and prostaglandins. Tear samplings have also been shown to contain elevated levels of eosinophil major basic protein. Eosinophils have been demonstrated in conjunctival scraping from 25% to 84% of patients with PAC and 43% of patients with SAC.

PROCEDURES

Scraping the conjunctival surface to look for eosinophils is a helpful diagnostic test. The procedure is done by placing a drop of topical anesthetic, such as tetracaine hydrochloride 0.5%, in the lower conjunctival sac. The anesthetic takes effect within 10 seconds. Using a platinum spatula, the inner surface of the lower lid is gently scraped several times. The material is then spread on a microscope slide. The slide is stained with Hansel stain, Giemsa stain, or one of the other common reagents. Slides are examined for the presence of eosinophils or eosinophil granules. Eosinophils are not ordinarily found in conjunctival scrapings from nonallergic individuals. The presence of even one eosino-

phil or eosinophil granule is considerable evidence in favor of a diagnosis of allergic conjunctivitis.¹⁹ The absence of eosinophils should not rule out a diagnosis of allergy. Eosinophils are often present in the deeper layers of the conjunctiva and may be absent or undetectable in the upper layers. The frequency of eosinophils in the conjunctival scrapings from patients with allergic conjunctivitis may vary from 20% to 80%³ depending on the patient population, the chronicity of the allergic condition, and the persistence of the examiner.³ Corneal infiltrates may occasionally be seen in severe allergic patients. They tend to be nummular, subepithelial, and peripheral.

Conjunctival provocation tests (CPT), which consist of instilling an offending pollen into the conjunctival sac, also produce the typical symptoms of hay fever conjunctivitis,⁴¹ and were the original method for evaluating allergic responses. Ocular challenge is used as a pharmacologic model for the evaluation of new antiallergic medications and immunotherapy.¹ The positivity of the challenge may be assessed by a sign and symptom scoring system that includes subjective and objective signs, such as conjunctival erythema, chemosis, tearing, and pruritus. The CPT has also been shown to have a relatively good reproducibility in both eyes.^{4, 41} Conjunctival provocation of ocular mast cells via opioid receptors has shown that 80% of normal patients reflect mast cell activation via the detection of the release of histamine (7 versus 18 nm/L) and prostaglandin D₂ (0 versus 273 ng/L). The release of these mediators can be blocked by pretreating the patients with cromolyn.¹⁰ To assess the potential usefulness of CPT as a diagnostic tool, it has been found that CPT directly correlated to radioallergosorbent test (RAST) in 71% (n = 130/83) of allergic patients. Of the 29% of uncorrelated cases, 23% (43/183) were positive for RAST but not for CPT whereas 6% (10/183) were positive by CPT but not by RAST.³¹ This suggests that there may be local sensitization of the target organ without evidence for systemic sensitization to the same antigen that clinically may reflect allergens causing ocular symptoms without any evidence of pulmonary or nasal allergic symptoms.

LATE-PHASE REACTION

A conjunctival late-phase reaction (LPR) has been described.^{6, 7, 30, 42} In the guinea pig model used by Leonardi,²⁹ the LPR manifested itself in several forms, including a classic biphasic response (33%), a multiphasic response (25%), and a single prolonged response (41%). The histologic evaluation of the conjunctiva revealed the typical influx of nonspecific cells of the inflammatory response, including neutrophils, basophils, and eosinophils. Tears collected from timed periods over the course of 6 hours after allergen challenge or CPT reflected the ability of mediators released during the LPR to reproduce the influx of cells that are commonly seen after ocular allergen testing⁸; however, clinical symptoms were not reproduced in this single patient. Direct application of leuko-

triene B₄ has been found to increase the number of eosinophils and neutrophils in rat conjunctiva.⁴² Ocular challenge with platelet-activating factor also results in an inflammatory response.²¹ The substantia propria was the primary site of the vascular changes, which included endothelial cell swelling, capillary dilatation, and edema. In one study, 7 of 10 patients revealed a resurgence of ocular symptoms 6 hours after the initial challenge. Scrapings of the conjunctiva revealed an influx of eosinophils, neutrophils, and lymphocytes; however, the study did not evaluate the total time sequence for the arrival of the cells into the conjunctiva, and some researchers have questioned whether this may be part of the initial immediate hypersensitivity reaction. Ocular challenge with histamine has revealed vascular permeability, but not an inflammatory response, as measured by the epithelial expression of intracellular adhesion molecule (ICAM; CD54).¹² In another study evaluating the efficacy of a new antihistamine, 14 of 22 patients (64%) developed signs and symptoms of an ocular LPR 2 to 9 hours after the ocular challenge dose.⁴⁶ In that study, the three most severe late-phase ocular reactions occurred in patients who had been previously treated with a topical antihistamine, although the itching score of the LPR was less than the immediate reaction. This observation raises the possibility that the topical H₁ antagonist used in that study blocked the immediate ocular response but permitted the administration of a higher dose of allergen in the ocular conjunctival challenge because the investigators were searching for an increased tolerance of allergen for an "immediate" reaction. In another study, loratadine was thought to have a protective effect on the LPR induced in the conjunctival provocation test.¹¹

TREATMENT

Antihistamines may be given systemically to relieve allergic symptoms. They may only partially relieve ocular symptoms, and patients often complain of side effects, such as drowsiness and dryness of the eyes, nose, and mouth. Antihistamines, such as antazoline and pheniramine, are available as eye drops and are usually combined with a topical vasoconstrictor, such as naphazoline hydrochloride. These antihistamine-vasoconstrictor eye drops are now available over the counter and are useful in treating mild allergic conjunctivitis. Most are used four times a day, and the side effects are minimal. They whiten the eyes by constricting the conjunctival blood vessels. They also relieve itching in the majority of patients.^{2, 19}

Four percent cromolyn (Opticrom, Crolom) has been a useful addition to the other drugs available for treating allergic conjunctivitis. Several studies have confirmed the therapeutic value of cromolyn in allergic conjunctivitis.^{15, 23} Usually, 10 to 14 days of treatment is necessary before optimal relief is obtained. Occasionally, patients notice improvement within 24 to 48 hours. Cromolyn is most useful for relief of mild and moderate symptoms of allergic conjunctivitis. More severe cases

may require the addition of topical corticosteroids. Unlike corticosteroids, cromolyn has minimal ocular side effects. An acute chemotic reaction to cromolyn has been reported in two patients,^{34, 35, 37} but as in the treatment of asthma, cromolyn side effects are rare. An extra benefit of cromolyn eye drops is the relief of nasal symptoms caused by the drainage of tear fluid into the nasal passages. Nedocromil sodium is available in Europe, and will soon be available in the United States for ophthalmic use.

Lodoxamide tromethamine 0.1% (Alomide) is a mast cell stabilizer which prevents the release of histamine and leukotrienes.^{39, 14} Lodoxamide inhibits mediator release from mast cells, presumably by inhibiting calcium influx, thereby indirectly inhibiting increased vascular permeability. It is 2500 times more potent than cromolyn in inhibiting mediator release from mast cells. It appears to be roughly equivalent to cromolyn, however, in controlling the symptoms of allergic conjunctivitis, vernal conjunctivitis and giant papillary conjunctivitis. It is preserved in benzalkonium chloride.

There have been two other antiallergic medications available over the past 2 years. Ketorolac tromethamine (Acular) 0.5% is a nonsteroidal anti-inflammatory drug (NSAID) that is preserved in benzalkonium chloride. It has been shown to relieve itching associated with allergic conjunctivitis. It also reduces levels of prostaglandin E_2 in tears. There may be some burning upon instillation. It is unexpected that an NSAID would relieve itching, but work by Woodward et al suggests that some of the prostaglandins, particularly PGE_2 and PGI_2 , may be pruritogenic.⁴⁵

Levocabastine hydrochloride (Livostin) is a potent antihistamine that blocks the H_1 histamine receptor.⁴⁶ It appears that the levoisomer of this compound has greater binding affinity and specificity than the dextroisomer; therefore, only the levoisomer is used in the preparation, which is a suspension. Levocabastine has been shown to be 65 times more potent than astemizole, and is associated with little irritation. It relieves the ocular itching associated with allergic conjunctivitis.

Corticosteroids may be extremely effective in relieving symptoms of allergic rhinitis, but because the disease is a chronic, recurrent, benign condition, these drugs should be used only in extreme situations. Topical steroids are associated with glaucoma, cataract formation, and infections of the cornea and conjunctiva.¹⁶ They should therefore be used with the greatest caution, and preferably, the patient should be monitored by an ophthalmologist. Under no circumstances should patients be allowed to use corticosteroid eye drops without medical supervision, nor should they be given prescriptions for unlimited refills.

Fluorometholone 0.1% eye drops are often selected as a useful treatment of external ocular inflammation. This steroid is highly effective in allergic conjunctivitis. It appears that fluorometholone penetrates the cornea well, but is inactivated quickly in the anterior chamber. Thus, the complications of fluorometholone are rare. It may be that fluorometholone is inactivated before it has an opportunity to combine with trabecular meshwork or lens receptors. Thus, the incidence of glaucoma

and cataract formation is expected to be lower than with prednisolone or dexamethasone.

Two "modified" steroids have recently been investigated for their efficacy in allergic conjunctivitis. Rimexolone (Vexol)²⁸ is a derivative of prednisolone that is quickly inactivated in the anterior chamber. During a 4-week treatment period in patients with uveitis, rimexolone caused an increase in intraocular pressure of 10 mm or more in 5% of patients whereas prednisolone acetate 1% caused elevation in nearly 14% of patients. In a 6-week steroid-responder study, 1% prednisolone and 0.1% dexamethasone caused mean pressures to rise to 30 mm Hg after 3 weeks. Rimexolone and fluorometholone caused mean pressures to rise to only 22 mm Hg at 3 weeks and 24 mm Hg at 6 weeks. Rimexolone has recently been approved for treatment of postcataract inflammation and for iritis.

Another modified corticosteroid that shows great promise is loteprednol etabonate (Lotemax).¹⁸ Lotemax also seems to be highly effective in allergic conjunctivitis, and is only rarely associated with a significant rise in intraocular pressure. It is expected to be approved for the treatment of ocular inflammation in 1997.

Other antiallergic drugs are being investigated and show promising results in the treatment of allergic conjunctivitis, including emedastine,³⁸ a selective blocker of the H₁ histamine receptor. Another H₁ blocker, olopatadine,³⁹ has mast cell stabilizing properties. It is currently being evaluated in patients with vernal conjunctivitis. Cyclosporine is a fungal antimetabolite that can be used as an anti-inflammatory drug.²⁴ It is used systemically to prevent rejection of various solid-tissue transplants. It has been used as an eye drop in a variety of conditions, including dry eye, high-risk corneal transplant patients, and vernal conjunctivitis. Cyclosporine appears to interfere with antigen processing and presentation of antigen to the uncommitted T lymphocytes.

CONCLUSION

Allergic conjunctivitis is common, especially during the allergy season. Ocular symptoms are usually accompanied by nasal symptoms, and there may be other allergic events in the patient's history that support the diagnosis of ocular allergy. Diagnostic tests can be helpful, especially conjunctival scrapings, to look for eosinophils. Consultation with the allergist to perform skin tests or in vitro tests may be useful and confirmatory in the diagnosis of ocular allergy. Symptoms may be mild, and many patients do not require treatment. If treatment is necessary, several antiallergic drugs are available. The selection of an antiallergic drug is based on the patient's need and a determination of which drug is well tolerated and most effective. A wealth of antiallergic drugs are available for the eye. Antihistamines, mast cell stabilizers, and NSAIDs are safe and reasonably effective. Corticosteroids are an order of magnitude more potent than noncorticosteroids; however, they have

attendant side effects that are best monitored by the ophthalmologist. The development of "modified" corticosteroids has been a boon to the treatment of ocular allergy because these drugs may reduce potential side effects without sacrificing potency.

References

1. Abelson MB, Smith LM: Evaluation in the histamine and compound 48/80 models of ocular allergy in humans. *Ophthalmology* 95:1494, 1988
2. Abelson MB, Allansmith MR, Friedlaender MH: Effects of topically applied ocular decongestant and antihistamine. *Am J Ophthalmol* 90:254, 1980
3. Abelson MB, Madiwale N, Weston JH: Conjunctival eosinophils in allergic ocular disease. *Arch Ophthalmol* 101:555, 1983
4. Aichane A, Campbell AM, Chanal I, et al: Precision of conjunctival provocation tests in right and left eyes. *J Allergy Clin Immunol* 92:49-55, 1993
5. Barney NP, Briggs RM, Bloch KJ, et al: Mast cell subpopulations in the conjunctiva. 66(14a)
6. Bonini S, Bonini S, Bucci MG: Allergen dose response and late symptoms in a human model of ocular allergy. *J Allergy Clin Immunol* 86:869-876, 1990
7. Bonini S, Bonini S, Vecchione A, et al: Inflammatory changes in the conjunctival scrapings after allergen provocation in humans. *J Allergy Clin Immunol* 82:462-469, 1988
8. Bonini S, Centofanti M, Schiavone M, et al: Passive transfer of the ocular late phase reaction. *Ocular Immunol Inflamm* 1:323-325, 1993
9. Caldwell DR, Verin P, Hartwich, Young R, et al: Efficacy and safety of Iodoxamide 0.1% vs. cromolyn sodium 4% in patients with vernal conjunctivitis. *Am J Ophthalmol* 113:632, 1992
10. Campbell AM, Demly P, Michel FB, et al: Conjunctival provocation tests with codeine phosphate: Effect of disodium cromoglycate. *Ann Allergy* 71:51-55, 1993
11. Ciprandi G, Buscaglia S, Marchesi E, et al: Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. *Int Arch Allergy Appl Immunol* 100:185-189, 1993
12. Ciprandi G, Buscaglia G, Pence GYP, et al: Ocular challenge and hyper-responsiveness to histamine in patients with allergic conjunctivitis. *J Allergy Clin Immunol* 91:1227-1230, 1993
13. Dart JK, Buckley RJ, Monnickendan M, et al: Perennial allergic conjunctivitis: Definition, clinical characteristics and prevalence: A comparison with seasonal allergic conjunctivitis. *Trans Ophthalmol Soc UK* 105:513-520, 1986
14. Fahy G, Easty DL, Collum L: Double-masked efficacy and safety evaluation of Iodoxamide 0.1% ophthalmic solution versus opticrom 2%: A multicenter study. *In Ophthalmology Today*. Amsterdam, Elsevier, 1988, p 341
15. Friday GA, Biglan AW, Hiles DA, et al: Treatment of ragweed: Allergic conjunctivitis with cromolyn sodium 4% ophthalmic solution. *Am J Ophthalmol* 95:169, 1983
16. Friedlaender MH: Corticosteroid therapy of ocular inflammation. *Int Ophthalmol Clin* 23:175, 1983
17. Friedlaender MH: Current concepts in ocular allergy. *Ann Allergy* 67:5-13, 1991
18. Friedlaender MH: Evaluation of loteprednol etabonate in giant papillary conjunctivitis. *Invest Ophthalmol Vis Sci* 36:S40, 1995
19. Friedlaender MH, Ohashi Y, Kelley J: Diagnosis of allergic conjunctivitis. *Arch Ophthalmol* 102:1198, 1984
20. Fukagawa K, Saito H, Tachimoto H, et al: RANTES production in cultured human conjunctival epithelial cell line. *J Allergy Clin Immunol* 97:441, 1996
21. George MA, Smith LM, Berry GJ, et al: Platelet activating factor induced inflammation following topical ocular challenge. *Invest Ophthalmol Vis Sci* 31:63, 1990

22. Gillette TE, Chandler JW, Geiner JV: Langerhans' cells of the ocular surface. *Ophthalmol* 89:700-711, 1982
23. Greenbaum J, Cockcroft D, Hargreave FE, et al: Sodium cromoglycate in ragweed: Allergic conjunctivitis. *J Allergy Clin Immunol* 59:437, 1977
24. Hakin KN, Ham J, Lightman SL: Use of cyclosporin in the management of steroid-dependent non-necrotizing scleritis. *Br J Ophthalmol* 75:340, 1991
25. Histamine levels of tears during allergic conjunctivitis: Physiopathology and therapy with disodium chromoglycate. *Chibret Int J Ophthalmol* 3:16, 1985
26. Isaacson P, Wright DH: Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. *Cancer* 53:2515-2524, 1984
27. Kari O, Sari OP, Halmepuro L, et al: Tear histamine during allergic conjunctivitis challenge. *Graefes Arch Clin Exp Ophthalmol* 223:60, 1985
28. Lehmann R, Assil K, Steward R, et al: Comparison of rimexolone 1% ophthalmic suspension to placebo in control of postcataract surgery inflammation. *Invest Ophthalmol Vis Sci* 36:S793, 1995
29. Leonardi A, Briggs RM, Bloch KJ, et al: Clinical patterns of ocular anaphylaxis in guinea pigs passively sensitized with IgG1 antibody. *Ophthalmic Res* 22:209-219, 1990
30. Leonardi A, Briggs RM, Bloch KJ, et al: Histology of the late-phase reaction in guinea pigs passively sensitized with IgG1 antibody. *Ophthalmic Res* 22:209-219, 1990
31. Leonardi A, Fregona IA, Gismondi M, et al: Correlation between conjunctival provocation test (CPT) and systemic allergometric tests in allergic conjunctivitis. *Eye* 4:760-764, 1990
32. Marks MB: Stigmata of Respiratory Tract Allergies. Kalamazoo, Upjohn, 1977, p 12
33. Marrache F, Brunet D, Frandeboeuf J, et al: The role of ocular manifestations in childhood allergy syndromes. *Rev Fr Allergol Immunol Clin* 18:151-155, 1978
34. Ostler HB: Acute chemotic reaction to cromolyn. *Arch Ophthalmol* 100:412, 1982
35. Ostler HB: Alpha 1-antitrypsin and ocular sensitivity to cromoglycate. *Lancet* 1:1287, 1982
36. Seto SK, Gillette T, Chandler JW: HLA-DR+ /T6⁻ Langerhans' cells of the human cornea. *Invest Ophthalmol Vis Sci* 28:1719-1722, 1987
37. Settipleane GA, Klein OE, Boyd CK, et al: Adverse reactions to cromolyn. *JAMA* 241:811, 1979
38. Sharif NA, Xu S, Yanni JM: Enedastine: Pharmacological profile of a novel antihistamine for use in allergic conjunctivitis. *Invest Ophthalmol Vis Sci* 36:S135, 1995
39. Sharif NA, Xu S, Yanni JM: Olopatadine (AL-4943A): Pharmacological profile of a novel antihistamine/antiallergic drug for use in allergic conjunctivitis. *Invest Ophthalmol Vis Sci* 37:S1027, 1996
40. Soukiasian SH, Rice B, Foster CS, et al: The T cell receptor in normal and inflamed human conjunctiva. *Invest Ophthalmol Vis Sci* 33:453-459, 1992
41. Stegman R, Miller D: A human model of allergic conjunctivitis. *Arch Ophthalmol* 93:1354, 1975
42. Trocmé SD, Bonini S, Barney NP, et al: Late phase reaction in topically induced ocular anaphylaxis in the rat. *Curr Eye Res* 7:437-469, 1988
43. Trocmé SD, Kephart GM, Allansmith MR, et al: Conjunctival deposition of eosinophil granule major basic protein in vernal conjunctivitis and contact lens-associated conjunctivitis. *Am J Ophthalmol* 108:57-63, 1989
44. Weeks ER: Epidemiology of hay fever and perennial allergic rhinitis. *Monogr Allergy* 21:1-20, 1987
45. Woodward DF, Nieves AL, Friedlaender MH: Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. *J Pharmacol Exp Ther* 279:137-142, 1996
46. Zuber P, Pecoud A: Effect of levocabastine, a new H₁ antagonist, in a conjunctival provocation test with allergens. *J Allergy Clin Immunol* 82:590-594, 1988

Address reprint requests to
 Mitchell H. Friedlaender, MD
 Division of Ophthalmology, MS214
 Scripps Clinic and Research Foundation
 10666 North Torrey Pines Road
 La Jolla, CA 92037